NCT02909361: Fulvestrant 500mg in Patients With Advanced Breast Cancer

NCT02909361
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER++
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Not Applicable
Drug Category: Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have ER++ tumor(s)
Exclusions: 
https://ClinicalTrials.gov/show/NCT02909361

Comments are closed.

Up ↑